rheumatoid arthritis

Rheumatoid Arthritis: Pharmacogenetics Approach

BioCertica Content Team

Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects joints but can also have systemic effects. It's characterized by painful swelling and can lead to joint deformity and erosion. According to the Arthritis Foundation, RA affects about 1% of the world's population, including over a million people in the United States alone. The management of RA is complex and varies significantly from person to person.

Current Challenges in Rheumatoid Arthritis Treatment

RA treatment often involves a combination of medications, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) like methotrexate. Biologic agents and Janus kinase (JAK) inhibitors are also used, especially in severe cases. However, the response to these treatments can be highly variable, with some patients experiencing only partial relief or significant side effects.

The Need for Personalized Treatment in RA

The efficacy and tolerability of RA medications can differ markedly among individuals. Factors like genetic makeup can influence how a patient metabolizes drugs, responds to treatment, and experiences side effects. This variability presents a challenge in achieving optimal treatment outcomes and underscores the need for a more personalized approach to RA management.

The Role of Pharmacogenetics in RA

Pharmacogenetics examines the role of genetics in drug response, offering valuable insights for personalized RA treatment. By understanding the genetic factors that influence responses to RA medications, pharmacogenetics enables clinicians to tailor treatments to individual patients, potentially improving efficacy and reducing adverse effects.

Gene-Drug Interactions in Rheumatoid Arthritis

Genetic variations can impact the effectiveness and safety of RA medications. For example, variations in genes like TPMT can influence a patient's response to methotrexate, a commonly used DMARD. BioCertica's pharmacogenetics report includes an analysis of these and other relevant genes, providing a more personalized approach to RA treatment.

The Benefits of BioCertica's Pharmacogenetics Report for RA Patients

BioCertica offers a pharmacogenetics report that analyzes genetic markers associated with the metabolism and response to RA medications. This report aids clinicians in selecting the most suitable medications and dosing strategies, enhancing the precision and effectiveness of RA treatment. For patients, this means a more targeted approach, potentially leading to better disease management and quality of life.


The management of rheumatoid arthritis is evolving with the integration of pharmacogenetics, offering a new level of personalized treatment. By leveraging the insights provided by BioCertica's pharmacogenetics report, healthcare providers can offer more effective, individualized care, significantly improving outcomes for RA patients.


1. StatPearls Publishing. (2023). Rheumatoid Arthritis. In StatPearls [Internet]. StatPearls Publishing. Available at: NCBI Bookshelf.

2. Aluko, A., & Ranganathan, P. (2022). Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis. In Methods in Molecular Biology (Vol. 2547, pp. 527-567). Springer. https://doi.org/10.1007/978-1-0716-2573-6_19 

Back to blog

Check out some of our DNA kits below.

1 of 3